https://doi.org/10.55788/937c8558
Prof. Thomas MacDonald (University of Dundee, UK) presented the results of the TIME study (ISRCTN18157641). The smaller Hygia study had previously suggested that there might be a substantial cardiovascular benefit of evening dosing of antihypertensive medication [2], and Prof. MacDonald explained that TIME aimed to test this hypothesis in a large prospective, randomised trial.
Participants already taking at least 1 antihypertensive medication were randomised 1:1 to take their usual antihypertensive medication in the morning (n=10,601) or the evening (n=10,503). The composite primary endpoint was hospitalisation for non-fatal myocardial infarction (MI) or non-fatal stroke, or vascular death. Information on hospitalisation and deaths was obtained from participants by email and through record linkage to national databases and further data was gathered from family doctors and hospitals, and independently adjudicated by a committee blinded to allocated dosing time.
The results showed that the time of dosing made no difference. With a median follow-up of 5.2 years, a primary endpoint event occurred in 3.4% of participants in the evening dosing group as opposed to 3.7% in the morning dosing group (HR 0.95; 95% CI 0.83–1.10; P=0.53). The results did not vary in pre-specified subgroup analyses.
Prof. MacDonald concluded: “TIME was one of the largest cardiovascular studies ever conducted and provides a definitive answer on the question of whether blood pressure lowering medications should be taken in the morning or evening. The trial clearly found that heart attack, stroke, and vascular death occurred at a similar degree, regardless of the time of administration. People with high blood pressure should take their regular antihypertensive medications at a time of day that is convenient for them and minimises any undesirable effects.”
- McDonald T, et al. TIME - The Treatment in Morning versus Evening study. Hot Line Session 1, ESC Congress 2022, Barcelona, Spain, 26–29 August.
- Hermida RC, et al. Eur Heart J. 2020;41(48):4565–4576.
Copyright ©2022 Medicom Medical Publishers
Posted on
Previous Article
« BOXing out oxygen and blood pressure targets Next Article
Cardiovascular assessment and management of patients undergoing non-cardiac surgery »
« BOXing out oxygen and blood pressure targets Next Article
Cardiovascular assessment and management of patients undergoing non-cardiac surgery »
Table of Contents: ESC 2022
Featured articles
ESC Clinical Practice Guidelines
Prevention of VT and sudden cardiac death: the new recommendations
New and first ESC cardio-oncology guideline
The 2022 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension
Cardiovascular assessment and management of patients undergoing non-cardiac surgery
Heart Failure
Old dogs, new tricks: Acetazolamide plus loop diuretics improves decongestion
No effect of neprilysin inhibition on cognition
Dapagliflozin DELIVERs for HFmrEF/HFpEF
Meta-analysis of DELIVER and EMPEROR-Preserved
Anticoagulation
Rheumatic heart disease-associated AF: standard-of-care holds ground
New anticoagulant safe and maybe effective: PACIFIC-AMI and PACIFIC-Stroke outcomes
AXIOMATIC-SSP: Reducing risk of ischaemic stroke with factor XIa inhibition?
Evolving evidence for P2Y12 inhibition in chronic coronary syndromes: PANTHER
Prevention
Danish study suggests starting CVD screening before age 70
Polypill SECUREs win in secondary prevention in elderly
Long-term therapy with evolocumab associated with lower CV mortality
ARBs + beta-blockers may delay Marfan syndrome aortic root replacement
ENTRIGUE: Subcutaneous pegozafermin in severe hypertriglyceridaemia
Artificial Intelligence & Digital Health – What Is New
First RCT evidence for use of AI in daily practice
AI-enhanced echography supports aortic stenosis patients
Ischaemia
Medical therapy versus PCI for ischaemic cardiomyopathy
Allopurinol disappoints in ALL-HEART
Conservative or invasive management for high-risk kidney disease patients with ischaemia?
Genotype-guided antiplatelet therapy in patients receiving PCI
Other HOTLINE Sessions
BOXing out oxygen and blood pressure targets
Coronary CT angiography diagnostics compared head-to-head
High-dose influenza vaccine: mortality benefit?
FFR-guided decision-making in patients with AMI and multivessel disease
Related Articles
October 27, 2022
Coronary CT angiography diagnostics compared head-to-head
August 26, 2022
Signs of heart disease may be more subtle in women than in men
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com